Does BPC-157 Lower Blood Pressure? What the Rat, Artery and Human Data Actually Show

Does BPC-157 lower blood pressure? Nothing published so far shows that it does in people. The research that exists points to something narrower and more interesting: in rats, BPC-157 left normal blood pressure unchanged but blunted the blood pressure spikes caused by a drug that blocks nitric oxide, and in isolated arteries, including human artery tissue, BPC-157 relaxes the vessel wall through the nitric oxide pathway. No clinical trial has ever tested BPC-157 as a treatment for high blood pressure, and the only published human safety data come from a handful of people.

What follows walks you through what BPC-157 is, how the nitric oxide connection works, what each blood pressure study actually measured, and why "BPC-157 for hypertension" is a claim the evidence does not support. If you are newer to the peptide, our guide BPC-157 for Women: Gut Health, Healing, and Recovery covers the gut and healing research in plain terms. This is educational content about published research rather than medical advice, BPC-157 is not an approved medicine, and you should never stop or change a blood pressure medication because of anything written about it.

BPC-157 is a synthetic peptide made of 15 amino acids, and its name stands for Body Protection Compound. The FDA's 2026 briefing document for its Pharmacy Compounding Advisory Committee describes BPC-157 as a pentadecapeptide fragment of the BPC protein originally isolated from human gastric juice, with research dating back to at least 1993 (fda.gov/media/193343/download).

What BPC-157 does, according to the research, is mostly a story told in animals. The same FDA document summarizes the preclinical literature as suggesting that BPC-157 prevents lesions in the gastrointestinal and cardiovascular systems of rodents, protects the kidneys, speeds tendon healing in rodents and has neuroprotective effects in rodent models of stroke and spinal cord injury. A 2025 systematic review by Vasireddi and colleagues in the HSS Journal, focused on musculoskeletal use, screened 544 articles and found that the evidence base is almost entirely preclinical, with 35 animal or lab studies set against 1 clinical study (doi.org/10.1177/15563316251355551).

That gap matters for every question about BPC-157, including blood pressure. For context on how BPC-157 is used alongside other recovery peptides, our review BPC-157 and TB-500 Together: What the Research Actually Shows About the Wolverine Stack looks at that pairing in detail.

BPC-157 appears to act on blood vessels mainly through nitric oxide (NO), the signaling molecule that the inner lining of your arteries, called the endothelium, releases to make the vessel wall relax. When an artery relaxes it widens, and wider arteries are one of the ways the body lowers blood pressure, which is the mechanistic reason people ask whether BPC-157 might lower blood pressure.

The clearest mechanism paper is a 2020 study in Scientific Reports by Hsieh and colleagues at Chang Gung University in Taiwan (doi.org/10.1038/s41598-020-74022-y). In isolated rat aorta, BPC-157 widened the vessel more as the concentration rose, and that effect weakened when the endothelium was removed. Adding L-NAME, a drug that blocks nitric oxide production, or hemoglobin, which mops up nitric oxide, blocked the effect. The authors traced the signal to a chain of proteins in which BPC-157 activated Src, Src loosened the grip of Caveolin-1 on endothelial nitric oxide synthase (eNOS), and the freed eNOS made nitric oxide. Their conclusion was that BPC-157 modulates the tone of an isolated aorta in a way that depends on both concentration and nitric oxide.

The Zagreb group that first described BPC-157 has argued for years that its relationship with the nitric oxide system is unusual. A 2014 review by Sikiric and colleagues in Current Pharmaceutical Design described BPC-157 as interacting with both nitric oxide blockers and nitric oxide precursors, rather than simply acting as a nitric oxide booster (doi.org/10.2174/13816128113190990411). The same review is candid about its limits, stating that how this "may be practically translated into an enhanced clinical performance remains to be determined."

In rats, BPC-157 did not lower normal blood pressure, but it did push back against drug induced blood pressure changes in both directions. That is the finding of the one study that measured systemic blood pressure directly, published by Sikiric and colleagues in the European Journal of Pharmacology in 1997 (doi.org/10.1016/s0014-2999(97)01033-9).

The researchers raised the rats' blood pressure with L-NAME at 5 mg/kg intravenously, which blocks the body's own nitric oxide production, and lowered it with L-arginine at 200 mg/kg, the raw material the body uses to make nitric oxide. BPC-157 was given at 10 µg/kg or 10 ng/kg. According to the abstract, BPC-157 had no effect on normal baseline values, while given beforehand it impaired the rise caused by L-NAME, and given 10 minutes after L-NAME, at the peak of the rise, it lowered the already raised values. BPC-157 pretreatment also prevented the moderate fall in blood pressure that L-arginine caused, but when BPC-157 was given 10 minutes after L-NAME and L-arginine together, its blood pressure effect disappeared.

In this model, then, BPC-157 behaved less like a blood pressure lowering drug and more like a stabilizer of a nitric oxide system that had been pushed out of balance. A drug that lowered blood pressure in general would be expected to lower normal blood pressure too, and BPC-157 did not.

BPC-157 prevented and reversed pulmonary hypertension in one rat model, which is a different condition from ordinary high blood pressure because the raised pressure sits in the arteries of the lungs. In a 2021 study in Biomedicines, Udovicic and colleagues gave rats monocrotaline at 80 mg/kg, a plant toxin that damages the lining of lung blood vessels and causes pulmonary arterial hypertension (doi.org/10.3390/biomedicines9070822). BPC-157 at 10 μg/kg or 10 ng/kg, started early (days 1 to 14 or days 1 to 30) or late (days 14 to 30), counteracted the measured changes, including the rise in right ventricle systolic pressure and the thickening of the small lung arteries, and the authors concluded that BPC-157 prevents and counteracts this toxin induced pulmonary hypertension in rats.

A 2022 review from the same group in Biomedicines places this result alongside rat studies of heart failure, arrhythmia and thrombosis (doi.org/10.3390/biomedicines10112696). These remain findings from a single laboratory in animals, they have not been repeated in people, and the monocrotaline model is a toxin injury rather than the slow pulmonary hypertension with many causes that doctors see in clinics.

BPC-157 does relax human arteries, but so far only in a dish. The first functional test in human arterial tissue, published in May 2026 in the Journal of Clinical Medicine by Yildirim and colleagues in Ankara, used leftover internal mammary artery segments from 12 patients having coronary bypass surgery (doi.org/10.3390/jcm15093488). The artery rings were contracted with phenylephrine and then exposed to rising concentrations of BPC-157 from 0.01 to 1 mg/mL.

BPC-157 relaxed the contracted human arteries more as the concentration went up. The relaxation was clearly stronger when the endothelium was intact, and blocking nitric oxide synthase with L-NAME blunted it, which matches the rat aorta findings. Some relaxation remained even without the endothelium, which the authors read as a sign that additional mechanisms are involved.

The authors were careful about what this means, describing their result as early mechanistic evidence and stating that "further molecular and in vivo studies are required to clarify its clinical relevance." An artery ring in an organ bath has no kidneys, no nervous system and no liver breaking the peptide down, and the 2025 systematic review reported a BPC-157 half life of less than 30 minutes, so it is an open question whether injected BPC-157 ever reaches your artery walls at concentrations like those used in the dish.

BPC-157 has never been tested with blood pressure as the outcome, because no randomized trial has measured whether it changes blood pressure in people with or without hypertension. The closest data come from safety monitoring in very small studies.

The only published intravenous study, a 2025 pilot by Lee and Burgess in Alternative Therapies in Health and Medicine, gave BPC-157 to 2 adults, a 58 year old man and a 68 year old woman, both of whom had received intravenous BPC-157 before (pubmed.ncbi.nlm.nih.gov/40131143). On day 1 they received 10 mg in 250 cc of saline over one hour, and on day 2 they received 20 mg, with vital signs and blood work checked before and after each infusion. The authors reported no side effects and no measurable effects on markers of the heart, liver, kidneys, thyroid or blood glucose, and the FDA's review of the same study notes that the authors "did not report any clinically significant changes in vital signs (BP or HR)."

Two people who had already used the peptide, followed for two days, cannot tell you whether BPC-157 lowers blood pressure, raises it or leaves it alone. The FDA's briefing also found a single phase 1 trial of oral BPC-157 tablets at 1 mg, 3 mg or 6 mg in healthy volunteers, registered on ClinicalTrials.gov as NCT02637284 with an estimated enrollment of 42, and in the FDA's words, "There are no results posted, and we were unable to find an associated published study."

BPC-157 is not a GLP-1 and does not act like one. GLP-1 medications such as semaglutide and tirzepatide are designed to mimic gut hormones that act on the GLP-1 receptor to regulate appetite and blood sugar, and they are FDA approved drugs. BPC-157 is a 15 amino acid fragment of a protein found in gastric juice, it is not FDA approved, and there is no evidence that it acts on the GLP-1 receptor.

The confusion probably comes from both being described as gut peptides and being sold through the same telehealth and compounding channels. The FDA has drawn a clear line, since its 2026 briefing concluded that "there is insufficient clinical safety information to characterize the safety profile" of BPC-157, and noted that as an injected or nasal peptide with 15 amino acids it may pose a significant risk for immunogenicity, meaning it could provoke an immune response.

Nobody knows whether BPC-157 is safe for people with high blood pressure, because it has never been studied in them. The 2025 systematic review in the HSS Journal stated plainly that "no clinical safety data were found" for BPC-157 in its musculoskeletal search, and it warned that adverse effects are possible because of unregulated manufacturing, contamination or unknown clinical safety. The same review notes that BPC-157 is banned in professional sports.

A 2026 review in Missouri Medicine by Moiz and colleagues at the University of Missouri, Kansas City and Saint Luke's Mid America Heart Institute listed BPC-157 among unapproved peptides that lack established human safety profiles, and it named product contamination, manufacturing impurities, inaccurate dosing and cardiovascular stress among the risks of the unregulated peptide market (pubmed.ncbi.nlm.nih.gov/42757290).

If you take blood pressure medication, the theoretical concern runs in a specific direction. If BPC-157 relaxed arteries in your body the way it does in a dish, combining it with drugs that already lower blood pressure could add to that effect, and that interaction has never been tested. If you are following any peptide protocol, a clinician who knows about it and checks your blood pressure and labs is the safer route, and our piece The Skin Gut Axis: How BPC-157 and Collagen Peptides Work from the Inside Out explains why gut focused BPC-157 research does not automatically translate to other organs.

The evidence is weak for any clinical blood pressure claim and moderate for the nitric oxide mechanism, as the table below shows.

Most of the animal work comes from one research group in Zagreb, which is the same group that discovered BPC-157. The rat aorta and human artery studies, from groups in Taiwan and Turkey, are independent confirmations of the mechanism, which strengthens the nitric oxide story, although neither tells you what a subcutaneous injection does to the blood pressure of a living person.

BPC-157 has a real and independently replicated effect on blood vessels, because it relaxes artery walls through the endothelial nitric oxide pathway in both rat and human tissue. In the one rat study that measured blood pressure directly, BPC-157 left normal blood pressure alone and acted more like a buffer against nitric oxide disruption than like a blood pressure lowering drug. Whether any of that happens in people has never been tested, so BPC-157 should not be thought of as a treatment for high blood pressure, and the FDA's own review says there is not enough clinical safety information to judge it. If your blood pressure is high, the medicines and lifestyle measures your clinician recommends are backed by evidence that BPC-157 simply does not have yet.

Sikiric P, et al. The influence of a novel pentadecapeptide, BPC 157, on NG nitro L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European Journal of Pharmacology, 1997. doi.org/10.1016/s0014-2999(97)01033-9

Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of the Src Caveolin 1 endothelial nitric oxide synthase pathway. Scientific Reports, 2020. doi.org/10.1038/s41598-020-74022-y

Yildirim AK, et al. Endothelium dependent nitric oxide mediated vasorelaxant effects of BPC 157 in human internal mammary artery. Journal of Clinical Medicine, 2026. doi.org/10.3390/jcm15093488

Udovicic M, et al. Stable gastric pentadecapeptide BPC 157 therapy for monocrotaline induced pulmonary hypertension in rats leads to prevention and reversal. Biomedicines, 2021. doi.org/10.3390/biomedicines9070822

Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 and NO system relation. Current Pharmaceutical Design, 2014. doi.org/10.2174/13816128113190990411

Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 as useful cytoprotective peptide therapy in the heart disturbances. Biomedicines, 2022. doi.org/10.3390/biomedicines10112696

Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Alternative Therapies in Health and Medicine, 2025. pubmed.ncbi.nlm.nih.gov/40131143

Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025. doi.org/10.1177/15563316251355551

Moiz A, O'Keefe EL, O'Keefe JH. Dangers of injectable peptides and other unregulated biohacking drugs. Missouri Medicine, 2026. pubmed.ncbi.nlm.nih.gov/42757290

U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23 and 24, 2026: BPC-157 related bulk drug substances. fda.gov/media/193343/download